This year’s EASD got off to a strong start with two deals announced this morning in the connected pen space, the first involving Medtronic and Novo Nordisk, the second between Abbott and Sanofi. Per the press releases;
‘Abbott (ABT) and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies will take an innovative approach to connected care by developing tools that combine the revolutionary FreeStyle Libre technology with Sanofi′s insulin dosing information for future smart pens, insulin titration apps and . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.